Infectious Complications in Pediatric, Adolescent and Young Adult Patients Undergoing CD19-CAR T Cell Therapy

被引:14
作者
Maron, Gabriela M. [1 ]
Hijano, Diego R. [1 ]
Epperly, Rebecca [2 ]
Su, Yin [3 ]
Tang, Li [3 ]
Hayden, Randall T. [4 ]
Naik, Swati [2 ]
Karol, Seth E. [5 ]
Gottschalk, Stephen [2 ]
Triplett, Brandon M. [2 ]
Talleur, Aimee C. [2 ]
机构
[1] St Jude Childrens Res Hosp, Dept Infect Dis, Memphis, TN USA
[2] St Jude Childrens Res Hosp, Dept Bone Marrow Transplantat & Cellular Therapy, Memphis, TN USA
[3] St Jude Childrens Res Hosp, Dept Biostat, Memphis, TN USA
[4] St Jude Childrens Res Hosp, Dept Pathol, Memphis, TN USA
[5] St Jude Childrens Res Hosp, Dept Oncol, Memphis, TN USA
来源
FRONTIERS IN ONCOLOGY | 2022年 / 12卷
基金
美国国家卫生研究院;
关键词
chimeric antigen receptor (CAR T); infection; immunotherapy; pediatric oncology; B-cell leukemia; CYTOKINE RELEASE SYNDROME; LEUKEMIA; CHILDREN; RISK;
D O I
10.3389/fonc.2022.845540
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
CD19-specific chimeric antigen receptor (CAR) T cell therapy has changed the treatment paradigm for pediatric, adolescent and young adult (AYA) patients with relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL). However, data on the associated infectious disease challenges in this patient population are scarce. Knowledge of infections presenting during treatment, and associated risk factors, is critical for pediatric cellular therapy and infectious disease specialists as we seek to formulate effective anti-infective prophylaxis, infection monitoring schemas, and empiric therapy regimens. In this work we describe our institutional experience in a cohort of 38 pediatric and AYA patients with CD19-positive malignancy treated with lymphodepleting chemotherapy (fludarabine/cyclophosphamide) followed by a single infusion of CD19-CAR T cells (total infusions, n=39), including tisagenlecleucel (n=19; CD19/4-1BB) or on an institutional clinical trial (n=20; CD19/4-1BB; NCT03573700). We demonstrate that infections were common in the 90 days post CAR T cells, with 19 (50%) patients experiencing a total of 35 infections. Most of these (73.7%) occurred early post infusion (day 0 to 28; infection density of 2.36 per 100 patient days-at-risk) compared to late post infusion (day 29 to 90; infection density 0.98 per 100 patient days-at-risk), respectively. Bacterial infections were more frequent early after CAR T cell therapy, with a predominance of bacterial blood stream infections. Viral infections occurred throughout the post infusion period and included primarily systemic reactivations and gastrointestinal pathogens. Fungal infections were rare. Pre-infusion disease burden, intensity of bridging chemotherapy, lymphopenia post lymphodepleting chemotherapy/CAR T cell infusion and development of CAR-associated hemophagocytic lymphohistiocytosis (carHLH) were all significantly associated with either infection density or time to first infection post CAR T cell infusion. A subset of patients (n=6) had subsequent CAR T cell reinfusion and did not appear to have increased risk of infectious complications. Our experience highlights the risk of infections after CD19-CAR T cell therapy, and the need for continued investigation of infectious outcomes as we seek to improve surveillance, prophylaxis and treatment algorithms.
引用
收藏
页数:12
相关论文
共 39 条
  • [1] Immune reconstitution and infectious complications following axicabtagene ciloleucel therapy for large B-cell lymphoma
    Baird, John H.
    Epstein, David J.
    Tamaresis, John S.
    Ehlinger, Zachary
    Spiegel, Jay Y.
    Craig, Juliana
    Claire, Gursharan K.
    Frank, Matthew J.
    Muffly, Lori
    Shiraz, Parveen
    Meyer, Everett
    Arai, Sally
    Brown, Janice
    Johnston, Laura
    Lowsky, Robert
    Negrin, Robert S.
    Rezvani, Andrew R.
    Weng, Wen-Kai
    Latchford, Theresa
    Sahaf, Bita
    Mackall, Crystal L.
    Miklos, David B.
    Sidana, Surbhi
    [J]. BLOOD ADVANCES, 2021, 5 (01) : 143 - 155
  • [2] Persistence of long-lived plasma cells and humoral immunity in individuals responding to CD19-directed CAR T-cell therapy
    Bhoj, Vijay G.
    Arhontoulis, Dimitrios
    Wertheim, Gerald
    Capobianchi, James
    Callahan, Colleen A.
    Ellebrecht, Christoph T.
    Obstfeld, Amrom E.
    Lacey, Simon F.
    Melenhorst, Jan J.
    Nazimuddin, Farzana
    Hwang, Wei-Ting
    Maude, Shannon L.
    Wasik, Mariusz A.
    Bagg, Adam
    Schuster, Stephen
    Feldman, Michael D.
    Porter, David L.
    Grupp, Stephen A.
    June, Carl H.
    Milone, Michael C.
    [J]. BLOOD, 2016, 128 (03) : 360 - 370
  • [3] Toxicities of chimeric antigen receptor T cells: recognition and management
    Brudno, Jennifer N.
    Kochenderfer, James N.
    [J]. BLOOD, 2016, 127 (26) : 3321 - 3330
  • [4] Late Events after Treatment with CD19-Targeted Chimeric Antigen Receptor Modified T Cells
    Cordeiro, Ana
    Bezerra, Evandro D.
    Hirayama, Alexandre V.
    Hill, Joshua A.
    Wu, Qian V.
    Voutsinas, Jenna
    Sorror, Mohamed L.
    Turtle, Cameron J.
    Maloney, David G.
    Bar, Merav
    [J]. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2020, 26 (01) : 26 - 33
  • [5] Toxicity and response after CD19-specific CAR T-cell therapy in pediatric/young adult relapsed/refractory B-ALL
    Curran, Kevin J.
    Margossian, Steven P.
    Kernan, Nancy A.
    Silverman, Lewis B.
    Williams, David A.
    Shukla, Neerav
    Kobos, Rachel
    Forlenza, Christopher J.
    Steinherz, Peter
    Prockop, Susan
    Boulad, Farid
    Spitzer, Barbara
    Cancio, Maria I.
    Boelens, Jaap Jan
    Kung, Andrew L.
    Szenes, Victoria
    Park, Jae H.
    Sauter, Craig S.
    Heller, Glenn
    Wang, Xiuyan
    Senechal, Brigitte
    O'Reilly, Richard J.
    Riviere, Isabelle
    Sadelain, Michel
    Brentjens, Renier J.
    [J]. BLOOD, 2019, 134 (26) : 2361 - 2368
  • [6] Kinetics of humoral deficiency in CART19-treated children and young adults with acute lymphoblastic leukaemia
    Deya-Martinez, A.
    Alonso-Saladrigues, A.
    Garcia, A. P.
    Faura, A.
    Torrebadell, M.
    Vlagea, A.
    Catala, A.
    Esteve-Sole, A.
    Juan, M.
    Rives, S.
    Alsina, L.
    [J]. BONE MARROW TRANSPLANTATION, 2021, 56 (02) : 376 - 386
  • [7] Revision and Update of the Consensus Definitions of Invasive Fungal Disease From the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium
    Donnelly, J. Peter
    Chen, Sharon C.
    Kauffman, Carol A.
    Steinbach, William J.
    Baddley, John W.
    Verweij, Paul E.
    Clancy, Cornelius J.
    Wingard, John R.
    Lockhart, Shawn R.
    Groll, Andreas H.
    Sorrell, Tania C.
    Bassetti, Matteo
    Akan, Hamdi
    Alexander, Barbara D.
    Andes, David
    Azoulay, Elie
    Bialek, Ralf
    Bradsher, Robert W., Jr.
    Bretagne, Stephane
    Calandra, Thierry
    Caliendo, Angela M.
    Castagnola, Elio
    Cruciani, Mario
    Cuenca-Estrella, Manuel
    Decker, Catherine F.
    Desai, Sujal R.
    Fisher, Brian
    Harrison, Thomas
    Heussel, Claus Peter
    Jensen, Henrik E.
    Kibbler, Christopher C.
    Kontoyiannis, Dimitrios P.
    Kullberg, Bart-Jan
    Lagrou, Katrien
    Lamoth, Frederic
    Lehrnbecher, Thomas
    Loeffler, Jurgen
    Lortholary, Olivier
    Maertens, Johan
    Marchetti, Oscar
    Marr, Kieren A.
    Masur, Henry
    Meis, Jacques F.
    Morrisey, C. Orla
    Nucci, Marcio
    Ostrosky-Zeichner, Luis
    Pagano, Livio
    Patterson, Thomas F.
    Perfect, John R.
    Racil, Zdenek
    [J]. CLINICAL INFECTIOUS DISEASES, 2020, 71 (06) : 1367 - 1376
  • [8] A proportional hazards model for the subdistribution of a competing risk
    Fine, JP
    Gray, RJ
    [J]. JOURNAL OF THE AMERICAN STATISTICAL ASSOCIATION, 1999, 94 (446) : 496 - 509
  • [9] Freifeld AG, 2011, CLIN INFECT DIS, V52, pE56, DOI 10.1093/cid/cir073
  • [10] Preemptive mitigation of CD19 CAR T-cell cytokine release syndrome without attenuation of antileukemic efficacy
    Gardner, Rebecca A.
    Ceppi, Francesco
    Rivers, Julie
    Annesley, Colleen
    Summers, Corinne
    Taraseviciute, Agne
    Gust, Juliane
    Leger, Kasey J.
    Tarlock, Katherine
    Cooper, Todd M.
    Finney, Olivia C.
    Brakke, Hannah
    Li, Daniel H.
    Park, Julie R.
    Jensen, Michael C.
    [J]. BLOOD, 2019, 134 (24) : 2149 - 2158